US Pharma MarketingA Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program in oncology R&D. But will the findings apply in more therapeutic areas?
Is AI finally proving its worth in drug R&D?
A Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program in oncology R&D. But will the findings apply in more therapeutic areas?
Source: PharmaVoice